-November 15, 2022
DUBLIN, Nov. 15, 2022 /PRNewswire/ – Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. launch of Medtronic Extended infusion set, the first and only infusion set labelled for up to 7-day wear. An infusion set is tubing that delivers insulin from an insulin pump to the body and typically requires a set change every two to three days.
-October 18, 2022
DUBLIN, Oct. 18, 2022 /PRNewswire/ – Medtronic plc (NYSE:MDT), the global leader in medical technology, is introducing a new program called My Insights exclusively made for individuals using the MiniMed™ 770G system. Using an individual's data, My Insights relies on the power of data science to provide personalized tips, trends, and reminders that customers can use to help with their diabetes management goals. The My Insights personalized recommendations are shared via a monthly email with educational content that is most relevant based on what an individual may currently be experiencing.
-December 22, 2021
Medicare coverage for Medtronic customers will be available 60 days after official publication
DUBLIN, Dec. 22, 2021 /PRNewswire/ – Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) will expand Medicare coverage for all types of continuous glucose monitors (CGMs), including adjunctive and non-adjunctive CGMs. This includes CGMs that integrate with Medtronic insulin pumps. The proposed rule was finalized on December 21, 2021 and will be effective starting 60 days after official publication.
-April 7, 2021
New Partnerships and Research Efforts Prioritized Over the Next Three Years to Address Health Disparities
April 7, 2021 - MINNEAPOLIS, /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its ongoing commitment to health equity for people of color living with diabetes. The company committed investments in partnerships with the American Diabetes Association® (ADA) and T1D Exchange, as well as additional research efforts, to better understand and address these disparities.
-October 28, 2020
October 28, 2020 – On October 27th, the Centers for Medicare & Medicaid Services (CMS) announced proposed new changes that, if finalized, would expand Medicare coverage for Continuous Glucose Monitors (CGMs) that provide critical information on glucose levels to help people with diabetes better manage their disease. We are very encouraged by CMS’s proposed rule and commend the agency on taking action to help more people with diabetes.
For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:
Janet Cho
Sr Director, Global Communications
818-576-5014
janet.cho@medtronic.com
Ashley Patterson
818-576-3025
ashley.a.patterson@medtronic.com
For all other media inquiries please select the appropriate Global Public and Media Relations contact